Abbott DBS Post-Market Study of Outcomes for Indications Over Time

Inclusion Criteria:

1. Subject is scheduled for a new implant or IPG device replacement surgery with amarket-released Abbott DBS system within 180 days.

2. Subject, or a legally acceptable representative, must provide written informedconsent prior to any study-related procedure.

Exclusion Criteria:

1. Subject is currently enrolled or plans to enroll in an investigational study thatmay confound the results of this study.

2. Subject has anatomic or comorbid conditions, or other medical, social, orpsychological conditions that, in the investigator's opinion, could limit thesubject's ability to participate in the study or to comply with follow-uprequirements, or impact the scientific soundness of the study results.

3. Study center is located in the United States, and indication for DBS implant is notParkinson's disease or disabling tremor.

4. Study center is located in the United States, and the intended lead implant locationis not at, or in close proximity to, the STN, GPi, or VIM thalamus.